Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Tucatinib in Healthy Subjects
NCT03723395Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucatinib in HER2-positive breast cancer and colorectal cancer (CRC) (5 arms), sponsored by Seagen Inc. Primary endpoints: Area under the concentration-time curve (AUC) from time 0 to infinity up to 22 days, AUC from time 0 to the time of the last quantifiable concentration up to 22 days and 5 more. Started Sep 2018; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03723395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723395.